Abstract
Hepatoblastoma (HB) is the most common primary malignant hepatic tumor of childhood and, occurring predominantly in the first two years of life. Approximately 100 cases are diagnosed every year in the United States of America. The management of HB has changed markedly over the last three decades. Alfa feto protein (AFP) and beta human chorionic gonadotrophin (beta HCG) are the main tumor markers and are markers for diagnosis and follow up. International collaborative efforts have led to the implementation of the Pre - Treatment Extent of the Disease PRETEXT staging system consensus classification to assess upfront resectability. Complete surgical resection plays a key role in successful management. Overall, outcomes have greatly improved over the past decades mainly because of advances in chemotherapy (CTR) agents and administration protocols, newer surgical approaches and liver transplantation (LT). Targeted medications towards the newly discovered β-catenin and Wnt genetic pathways in tumor cells may soon become an option for treatment. The current disease free survival (DFS) rates are approaching 85%. For the 25% of patients with metastasis at presentation, the overall survival (OS) remains poor. A more individualized approach to treating the heterogeneous spectrum of HB may become the basis of successful treatment in complex cases. Newer medications and surgical techniques are being exploited. Here we present a comprehensive review of the recent advances in the management of HB. A wide literature search was made using internet search engines such as PubMed and Google scholar. More than 100 articles were reviewed and the information extrapolated was arranged to produce this review.
Keywords: Alfa fetoprotein, β-catenin, cisplatin, hepatoblastoma, liver transplantation, pretext.
Graphical Abstract
[1]
Benjamin E, Lendon M, Marsden HB. Hepatoblastoma as a cause of intrauterine fetal death. Case report. Br J Obstet Gynaecol 1981; 88(3): 329-32.
[2]
Spyridakis I, Kepertis C, Lampropoulos V, Mouravas V, Filippopoulos A. Embryonal/Fetal subtype hepatoblastoma: A case report. J Clin Diagn Res 2014; 8(9): ND01-2.
[http://dx.doi.org/10.7860/JCDR/2014/6643.4823]
[http://dx.doi.org/10.7860/JCDR/2014/6643.4823]
[3]
Pateva IB, Egler RA, Stearns DS. Hepatoblastoma in an 11-year-old: Case report and a review of the literature. Medicine (Baltimore) 2017; 96(2)e5858
[http://dx.doi.org/10.1097/MD.0000000000005858]
[http://dx.doi.org/10.1097/MD.0000000000005858]
[4]
Rougemont AL, McLin VA, Toso C, Wildhaber BE. Adult hepatoblastoma: Learning from children. J Hepatol 2012; 56(6): 1392-403.
[5]
Remes-Troche JM, Montaño-Loza A, Meza-Junco J, García-Leiva J, Torre-Delgadillo A. Hepatoblastoma in adult age. A case report and literature review. Ann Hepatol 2006; 5(3): 179-81.
[6]
Conran RM, Hitchcock CL, Waclawiw MA, Stocker JT, Ishak KG. Hepatoblastoma: The prognostic significance of histologic type. Pediatr Pathol 1992; 12: 167-83.
[7]
Rai P, Feusner J. Cerebral metastasis of hepatoblastoma: A review. J Pediatr Hematol Oncol 2016; 38(4): 279-82.
[9]
Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolokin MH, Mayers RL. Hepatoblastoma state of the art: Pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26(1): 19-28.
[10]
Koh KN, Park M, Kim BE, et al. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma. Pediatr Blood Cancer 2011; 57(4): 554-60.
[11]
Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: A revised staging system for primary malignant liver tumors of childhood developed by the SIOPEL group. Pediatr Radiol 2007; 37: 123-32.
[12]
Katzenstein HM. Chemotherapeutic approaches for newly diagnosed hepatoblastoma: Past, present, and future strategies. Pediatr Blood Cancer 2012; 59(5): 809-12.
[13]
Khaderi S, Guiteau J, Cotton RT, O’Mahony C, Rana A, Goss JA. Role of liver transplantation in the management of hepatoblastoma in the pediatric population. World J Transplant 2014; 4(4): 294-8.
[14]
Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: An update. Curr Opin Pediatr 2014; 26(3): 362-9.
[15]
Bell D, Ranganathan S, Tao J, Monga SP. Novel advances in understanding of molecular pathogenesis of hepatoblastoma: A Wnt/β-catenin perspective. Gene Expr 2017; 17(2): 141-54.
[16]
Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003; 38(3): 560-6.
[17]
Takayasu H, Horie H, Hiyama E, et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histo-logy in childhood hepatoblastoma. Clin Cancer Res 2001; 7(4): 901-8.
[18]
Czauderna P, Haeberle B, Hiyama E, Rangaswami A, Krailo M, Rudolf Maibach R. The Children’s Hepatic Tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 2016; 52: 92-101.
[19]
Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Extrom TJ. Expression, prooter usage and parental imprinting status of insulin-like growth factor 2 (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 1995; 11: 221-9.
[20]
Ahmad N, Wheeler K, Stewart H, Campbell C. Hepatoblastoma in a mosaic trisomy 18 child with hemihypertrophy. BMJ Case Rep 2016; 2016bcr 2015211380
[http://dx.doi.org/10.1136/bcr-2015-211380.]
[http://dx.doi.org/10.1136/bcr-2015-211380.]
[21]
Fukuzawa R, Umezawa A, Ochi K, Urano F, Ikeda H, Hata J. High frequency of inactivation of the imprinted H19 gene in “sporadic” hepatoblastoma. Int J Cancer 1999; 82: 490-7.
[22]
Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet 1992; 43: 1023-5.
[23]
Oda H, Imai Y, Nakatsuru Y, Hata J, Ishikawa T. Somatic mutations of the APC gene in sporadic hepatoblastoma. Cancer Res 1996; 56: 3320-3.
[25]
Cadigan KM, Nusse R. Wnt signaling: A common theme in animal development. Genes Dev 1997; 11(24): 3286-305.
[26]
Monga SP. Role and regulation of β-catenin signaling during physiological liver growth. Gene Expr 2014; 16(2): 51-62.
[27]
Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP. Conditional deletion of β-catenin reveals its role in liver growth and regeneration. Gastroenterology 2006; 131(5): 1561-72.
[28]
Monga SP. β-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 2015; 148(7): 1294-310.
[29]
Lade AG, Monga SP. β-catenin signaling in hepatic development and progenitors: Which way does the WNT blow? Dev Dyn 2011; 240(3): 486-500.
[30]
Tan X, Yuan Y, Zeng G, et al. Beta-catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development. Hepatology 2008; 47(5): 1667-79.
[31]
Armengol C, Cairo S, Fabre M, Buendia MA. Wnt signaling and hepatocarcinogenesis: The hepatoblastoma model. Int J Biochem Cell Biol 2011; 43(2): 265-70.
[32]
Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14(6): 471-84.
[33]
Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999; 59(2): 269-73.
[34]
Koch A, Weber N, Waha A, et al. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. J Pathol 2004; 204(5): 546-54.
[35]
Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr Blood Cancer 2006; 47(6): 811-8.
[36]
Koch A, Waha A, Hartmann W, et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 2005; 11(12): 4295-304.
[37]
Eichenmuller M, Trippel F, Kreuder M, et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol 2014; 61(6): 1312-20.
[38]
McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC, Zdeb MS. Maternal and infant birth characteristics and hepatoblastoma. Am J Epidemiol 2006; 163(9): 818-28.
[39]
Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012; 59(5): 776-9.
[40]
Tanaka Y, Inoue T, Horie H. International pediatric liver cancer pathological classification: Current trend. Int J Clin Oncol 2013; 18(6): 946-54.
[41]
Buccoliero AM, Castiglione F, Maio V, et al. Teratoid hepatoblastoma. Fetal Pediatr Pathol 2008; 27(6): 274-81.
[42]
Fasano M, Theise ND, Nalesnik M, Goswami S. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen. Mod Pathol 1998; 11(10): 934-8.
[43]
Von Schweinitz D, Hecker H, Schmidt-von-Arndt G, Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 1997; 74(6): 593-9.
[44]
Davies JQ, de la Hall PM, Kaschula RO, et al. Hepatoblastoma —Evolution of management and outcome and significance of histo-logy of the resected tumor. A 31-year experience with 40 cases. J Pediatr Surg 2004; 39(9): 1321-7.
[45]
Fuchs J, Rydzynski J, Von Schweinitz D, et al. Study Committee of the Cooperative Pediatric Liver Tumor Study (Hb 94) for the German Society for Pediatric Oncology and Hematology. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002; 95(1): 172-82.
[46]
Imbach P. Hepatic tumors. In:Pediatric Oncology. Springer Science Business Media 2004; pp. 187-91.
[47]
Duffy KA, Deardorff MA, Kalish JM. The utility of alpha-fetoprotein screening in Beckwith-Wiedemann syndrome. Am J Med Genet A 2017; 173(3): 581-4.
[48]
Baheti AD, Luana Stanescu A, Li N, Chapman T. Contrast-enhanced CT features of hepatoblastoma: Can we predict histopathology? Clin Imaging 2017; 44: 33-7.
[49]
Bieze M, van Gulik TM, Bennink RJ. Hepatoblastoma evaluated by 18F-fluoromethyl choline PET/CT. Clin Nucl Med 2013; 38(2): e80-2.
[http://dx.doi.org/10.1111/hpb.12087]
[http://dx.doi.org/10.1111/hpb.12087]
[50]
Crich SG, Landzardoy S, Alberti D, et al. Magnetic Resonance Imaging Detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles1. Neoplasia 2007; 9: 1046-56.
[51]
Cistaro A, Treglia G, Pagano M, et al. A comparison between 18F-FDG PET/CT imaging and biological and radiological findings in restaging of hepatoblastoma patients. BioMed Res Int 2013; 2013709037
[http://dx.doi.org/10.1155/2013/709037]
[http://dx.doi.org/10.1155/2013/709037]
[52]
Zhuang H, Peng YL, Chen TW, Jiang Y. The comparison of grey-scale ultrasonic and clinical features of hepatoblastoma and hepatocellular carcinoma in children: A retrospective study for ten years. BMC Gastroenterol 2011; 11: 78.
[53]
Samim M, El-Haddad GE, Molenaar IQ, et al. [18F] Fluorodeoxyglucose PET for interventional oncology in liver malignancy. PET Clin 2014; 9(4): 469-95.
[54]
Vlajnic T, Brisse HJ, Aerts I, et al. Fine needle aspiration in the diagnosis and classification of hepatoblastoma: Analysis of 21 New Cases. Diagn Cytopathol 2017; 45(2): 91-100.
[55]
Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18(14): 2665-75.
[56]
Maruyama K. Serum α-fetoprotein concentration in extremely low-birthweight infants. Pediatr Int (Roma) 2017; 59(2): 159-62.
[57]
Zhou S, O’Gorman MR, Yang F, Andresen K, Wang L. Glypican 3 as a serum marker for hepatoblastoma. Sci Rep 2017; 7: 45932.
[http://dx.doi.org/10.1038/srep45932]
[http://dx.doi.org/10.1038/srep45932]
[58]
Yamaguchi H, Ishii E, Hayashida Y, et al. Mechanism of thrombocytosis in hepatoblastoma: A case report. Pediatr Hematol Oncol 1996; 13(6): 539-44.
[59]
Unal E, Koksal Y, Akcoren Z, et al. Mesenchymal hamartoma of the liver mimicking hepatoblastoma. J Pediatr Hematol Oncol 2008; 30(6): 458-60.
[60]
Ramanujam TM, Ramesh JC, Goh DW, et al. Malignant transformation of mesenchymal hamartoma of the liver: Case report and review of the literature. J Pediatr Surg 1999; 34(11): 1684-6.
[61]
Putra J, Ornvold K. Undifferentiated embryonal sarcoma of the liver: A concise review. Arch Pathol Lab Med 2015; 139(2): 269-73.
[62]
Mohapatra N, Krisnanand BR. Embryonal sarcoma of liver: An undifferentiated rare primary solid and mucoid to cystic tumor. Indian J Pathol Microbiol 2007; 50(4): 811-3.
[63]
Browne M, Sher D, Grant D, et al. Survival after liver transplantation for hepatoblastoma: A 2-center experience. J Pediatr Surg 2008; 43(11): 1973-81.
[64]
Meyers RL, Tiao G, de Ville de Goyet J, Superina R, Aronson DC. Hepatoblastoma state of the art: Pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr 2014; 26(1): 29-36.
[65]
Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases: Treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000; 89(8): 1845-53.
[66]
Venkatramani R, Stein JE, Sapra A, Genyk Y. Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma. Br J Surg 2015; 102(1): 108-13.
[67]
Zsíros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study. J Clin Oncol 2010; 28(15): 2584-90.
[68]
Watanabe K. Current chemotherapeutic approaches for hepatoblastoma. Int J Clin Oncol 2013; 18(6): 955-61.
[69]
Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009; 361(17): 1662-70.
[70]
Zhang YT, Feng LH, Zhong XD, Wang LZ, Chang J. Vincristine and irinotecan in children with relapsed hepatoblastoma: A single-institution experience. Pediatr Hematol Oncol 2015; 32(1): 18-25.
[71]
Katzenstein HM, Furman WL, Malogolowkin MH, et al. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children’s Oncology Group AHEP0731 study committee. Cancer 2017; 123(12): 2360-7.
[72]
Blouin P, Brugières L, Tabone MD, et al. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma. Pediatr Blood Cancer 2004; 42(2): 149-54.
[73]
Lieber J, Eicher C, Wenz J, et al. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer 2011; 11: 362.
[74]
Provenzi M, Saettini F, Conter V, et al. Is there a role for high dose chemotherapy and blood stem cell rescue in childhood hepatoblastoma presenting with lung metastases? A case report and literature review. Ital J Pediatr 2013; 39: 65.
[75]
Habrand JL, Nehme D, Kalifa C, et al. Is there a place for radiation therapy in the management of hepatoblastomas and hepatocellular carcinomas in children? Int J Radiat Oncol Biol Phys 1992; 23(3): 525-3.
[76]
Ueda Y, Hiyama E, Kamimatsuse A, Kamei N. Wnt signaling and telomerase activation of hepatoblastoma: Correlation with chemo-sensitivity and surgical respectability. J Pediatr Surg 2011; 46(12): 2221-7.
[77]
Ilmer M, Garnier A, Vykoukal J, et al. Targeting the neurokinin-1 receptor compromises canonical Wnt signaling in hepatoblastoma. Mol Cancer Ther 2015; 14(12): 2712-21.
[78]
Shi Y, Commander SJ, Masand PM, Heczey A, Goss JA, Vasudevan SA. Vascular inavsion is a prognostic indicator in hepatoblastoma. J Pediatr Surg 2017; 52(6): 956-61.
[79]
Krstovski N, Radlović N, Janić D, Dokmanović L, Smoljanic Z, Sretenovic A. Successful treatment of second hepatoblastoma relapse - case report. Acta Chir Iugosl 2009; 56(2): 105-8.
[80]
Shi Y, Geller JI, Ma IT, et al. Relapsed hepatoblastoma confined to the lung is effectively treated with pulmonary metastasectomy. J Pediatr Surg 2016; 51(4): 525-9.
[81]
Semeraro M, Branchereau S, Maibach R, et al. Relapses in hepatoblastoma patients: Clinical characteristics and outcome--experience of the International Childhood Liver Tumor Strategy Group (SIOPEL). Eur J Cancer 2013; 49(4): 915-22.
[82]
Van Laarhoven S, van Baren R, Tamminga RY, de Jong KP. Radiofrequency ablation in the treatment of liver tumors in children. J Pediatr Surg 2012; 47(3): e7-e12.
[http://dx.doi.org/10.1102/1470-7330.2009.9041]
[http://dx.doi.org/10.1102/1470-7330.2009.9041]
[83]
Ye J, Shu Q, Li M, Jiang TA. Percutaneous radiofrequency ablation for treatment of hepatoblastoma recurrence. Pediatr Radiol 2008; 38(9): 1021-3.
[84]
Busweiler LA, Wijnen MH, Wilde JC, et al. Surgical treatment of childhood hepatoblastoma in the Netherlands (1990-2013). Pediatr Surg Int 2017; 33(1): 23-31.
[85]
Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: A report from the Children’s Oncology Group. J Clin Oncol 2011; 29(24): 3301-6.
[86]
Hirakawa M, Nishie A, Asayama Y, et al. Efficacy of preoperative transcatheter arterial chemoembolization combined with systemic chemotherapy for treatment of unresectable hepatoblastoma in children. Jpn J Radiol 2014; 32(9): 529-36.
[87]
Hishiki T, Watanabe K, Ida K, et al. The role of pulmonary metastasectomy for hepatoblastoma in children with metastasis at diagnosis: Results from the JPLT-2 study. J Pediatr Surg 2017; 52(12): 2051-5.
[88]
Wiederkehr JC, Avilla SG, Mattos E, et al. Associating liver partition with portal vein ligation and staged hepatectomy (ALPPS) for the treatment of liver tumors in children. J Pediatr Surg 2015; 50(7): 1227-31.
[89]
Gunsar F. Liver transplantation for hepatocellular carcinoma beyond the milan criteria. Exp Clin Transplant 2017; 15(Suppl. 2): 59-64.
[90]
De Ville de Goyet J, Meyers RL, Tiao GM, Morland B. Beyond the Milan criteria for liver transplantation in children with hepatic tumours. Lancet Gastroenterol Hepatol 2017; 2(6): 456-62.
[91]
Wu JF, Chang HH, Lu MY, et al. Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma. J Biomed Sci 2017; 24(1): 62.
[92]
Kiruthiga KG, Ramakrishna B, Saha S, Sen S. Histological and immunohistochemical study of hepatoblastoma: Correlation with tumor behavior and survival. J Gastrointest Oncol 2018; 9(2): 326-37.
[93]
Saettini F, Conter V, Provenzi M, et al. Is multifocality a prognostic factor in childhood hepatoblastoma? Pediatr Blood Cancer 2014; 61(9): 1593-7.
[94]
Dall’Igna P, Brugieres L, Christin AS, et al. Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL group. Pediatr Blood Cancer 2018; 65(1): 1.
[http://dx.doi.org/10.1002/pbc.26791]
[http://dx.doi.org/10.1002/pbc.26791]
[95]
Hussain AE, Blakley BW, Nicolas M, Balderston J. Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol 2003; 32(5): 294-7.
[96]
Landier W, Armenian S, Bhatia S. Late effects of childhood cancer and its treatment. Pediatr Clin North Am 2015; 62(1): 275-300.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
13